Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers drug discovery, CMC development, preclinical research, biology, chemistry, catalyst screening, flow chemistry, carbohydrate chemistry, analytical chemical, ADME/DMPK, pharmacology, safety assessment, IND-Enabling studies, and advanced technology services. The company also provides peptide, SiRNA, ADC, Protac, AOCs, NAMs Platforms. The company was founded in 2004 and is based in Shanghai, China.
Research context
Shanghai Medicilon Inc appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Shanghai Medicilon Inc is currently in a long term uptrend where the price is trading 44.0% above its 200 day moving average.
From a valuation standpoint, the stock is 251.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 33.8.
Shanghai Medicilon Inc's total revenue rose by 26.6% to $173M since the same quarter in the previous year.
Its net income has increased by 41.2% to $28M since the same quarter in the previous year.
Finally, its free cash flow grew by 704.9% to $36M since the same quarter in the previous year.
Based on the above factors, Shanghai Medicilon Inc gets an overall score of 4/5.